bioAffinity Technologies (NASDAQ: BIAF) to showcase CyPath Lung poster on Stage 1A lung cancer

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reported that it will present a scientific poster titled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights three clinical cases in which CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients whose presentations were atypical and diagnostically challenging. The company announced this upcoming presentation in a press release dated December 3, 2025, and has filed both the press release and the poster as exhibits.

false 0001712762 0001712762 2025-12-03 2025-12-03 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-12-03 2025-12-03 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-12-03 2025-12-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 3, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 3, 2025, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that it will present a poster entitled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” (the “Poster”) at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The Poster showcases three cases in which CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations.

Copies of the press release and Poster are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated December 3, 2025
99.2		Poster entitled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence”
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 3, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did bioAffinity Technologies (BIAF) announce in this 8-K filing?

bioAffinity Technologies announced that it will present a poster titled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.

What is CyPath Lung as described by bioAffinity Technologies (BIAF)?

CyPath® Lung is described as a noninvasive sputum-based flow cytometry test used to help identify lung cancer.

What clinical results does the CyPath Lung poster highlight for BIAF?

The poster showcases three cases in which CyPath® Lung successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations.

When and where will bioAffinity Technologies present the CyPath Lung poster?

The poster will be presented at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.

What exhibits are included with this bioAffinity Technologies 8-K filing?

The exhibits include a press release dated December 3, 2025 (Exhibit 99.1) and the poster titled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” (Exhibit 99.2), along with the cover page interactive data file (Exhibit 104).

Does this 8-K filing from bioAffinity Technologies disclose any financial results or major transactions?

No financial results or major transactions are described; the filing focuses on the planned presentation of CyPath® Lung clinical case results and the related press release and poster exhibits.